This trial is active, not recruiting.

Condition rotatory cuff calcific tendonitis
Treatments methylprednisolone acetate, triamcinolone acetonide
Phase phase 4
Sponsor Istituto Ortopedico Rizzoli
Collaborator Azienda Ospedaliera San Giovanni Battista
Start date March 2012
End date December 2012
Trial size 40 participants
Trial identifier NCT01652495, 2012-000866-40


The purpose of this study is to compare the efficacy and effects on the hypothalamus-pituitary-adrenal axis of a single intrabursal injection of two different types of corticosteroids (methylprednisolone and triamcinolone) in patients with calcific shoulder tendinopathy.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation randomized
Endpoint classification safety/efficacy study
Intervention model parallel assignment
Masking single blind (subject)
Primary purpose treatment
(Active Comparator)
Single intrabursal injection of methylprednisolone acetate
methylprednisolone acetate Depo-medrol
Single intrabursal ultrasound guided injection
(Active Comparator)
Single intrabursal injection of Triamcinolone acetonide
triamcinolone acetonide Triamvirgi
Single intrabursal ultrasound guided injection

Primary Outcomes

Degree of functional improvement
time frame: 0, 1, 7, 15, 30 and 45 days after treatment

Secondary Outcomes

Suppression of hypothalamus-pituitary-adrenal axis
time frame: 0, 1,7, 15, 30 and 45 days after treatment

Eligibility Criteria

Male or female participants from 18 years up to 70 years old.

Inclusion Criteria: - painful rotator cuff calcific tendonitis demonstrated by ultrasounds Exclusion Criteria: - pregnancy - use of corticosteroids in the previous 2 months - systemic chronic inflammatory or allergic diseases - allergy to methylprednisolone or triamcinolone - diabetes - glaucoma - coagulopathies or current treatment with antiaggregants or anticoagulants - septic arthritis or infections - calcific enthesopathy

Additional Information

Official title Evaluation of Efficacy and Hypothalamus-pituitary-adrenal Axis Suppression Due to a Single Intrabursal Injection of Corticosteroids in Patients With Shoulder Calcific Tendinopathy
Description Rotator cuff calcific tendonitis is a common disease, mainly affecting women aged 30 to 50 years old. It is associated to severe pain and impotence. US-guided percutaneous treatment is considered the gold standard treatment with the aim to destroy and wash out shoulder's calcification, responsible for inflammation, pain and functional limitation. Corticosteroids are injected in the subacromial-subdeltoid bursa at the end of the procedure to facilitate the prompt pain relief and functional recovery. Although corticosteroids represent the most powerful drugs to reduce inflammation and pain, their use is associated to important side effects, mainly the suppression of the hypothalamus-pituitary-axis (HPA). At the same time, no standardized protocols exist regarding the best type and dose of corticosteroid to be injected in association to the above mentioned treatment, nor data evaluating the exact duration of HPA suppression following a single intrabursal injection of corticosteroids. 40 patients affected by rotator cuff calcific tendonitis will be enrolled in the study and randomly assigned to two groups: one group (20 patients) will be treated with a single intrabursal injection of 40 mg of methylprednisolone; the other group (20 patients) will be treated with a single intrabursal injection of 40 mg of triamcinolone. All patients will be tested at time 0 (morning before treatment) and at 1, 7, 15, 30 and 45 days after the injection, using clinical, laboratory and US parameters in order to compare the efficacy and safety of the two drugs.
Trial information was received from ClinicalTrials.gov and was last updated in January 2013.
Information provided to ClinicalTrials.gov by Istituto Ortopedico Rizzoli.